Cardiac amyloidosis continues to get more and more attention at cardiology meetings. At Heart Failure 2026 in Spain, it was the topic of multiple studies, including one on the benefits of acoramidis.
Up to 30% of U.S. patients carry genetic variations that reduce the effectiveness of clopidogrel, an antiplatelet medication sold under the brand name Plavix.
This new catheter-based device for lymphatic drainage showed early potential to be an effective treatment option for acute decompensated heart failure.
The REVEAL study has been assessing the sensitivity and specificity of iodine 124 evuzamitide (I 124 evuzamitide), a PET agent capable of visualizing signs of cardiac amyloidosis on imaging.
Those who undergo repeated exams before the age of 6 face almost double the risk of later developing intracranial tumors, leukemia or lymphoma, according to new data.
That’s according to an award-winning scientific online poster presented this week during the American Roentgen Ray Society’s annual meeting being held in Honolulu, Hawaii.
The hope is that the technique could lead to earlier detection of diseases by simultaneously identifying structural and functional abnormalities that standard ultrasound imaging methods alone cannot.
Features pertaining to location, density and superimposed structures were recently found to be associated with poorer outcomes for patients who initially had their lung cancer overlooked on radiographs.
![A majority of medical devices involved in Class I recalls were never required by the U.S. Food and Drug Administration (FDA) to undergo premarket or postmarket clinical testing, according to new research published in Annals of Internal Medicine.[1]](/sites/default/files/styles/top_stories/public/2024-09/istock-1209664264.jpg.webp?itok=gQInU1vO)
